Nebenwirkungen · Lazcluze
Lazcluze 80 mg film-coated tablets Lazcluze 240 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 11
HOS-151425 · Präparat HOS-100535
Rash (including dermatitis acneiform), pruritus and dry skin has occurred. Rash occurred in 89% of patients treated with lazertinib in combination with amivantamab. Most cases were Grade 1 or 2, with Grade 3 events occurring in 27% of patients. Rash leading to any treatment discontinuation occurred in 6% of patients. Rash usually developed within the first 4 weeks of therapy, with a median time to onset of 14 days. Nail toxicity occurred in patients treated with lazertinib in combination with amivantamab. Most events were Grade 1 or 2, with Grade 3 nail toxicity occurring in 11% of patients (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-12T16:08:31Z · SHA-256 1473f5edd2523c74fb17bb2ceb92aa90b2ceba65343d261aad9177ebf723dcbf · Passage 69f8f3b4b9889c65501a6454b06ea79b99415ea476eeb466b8e4bf5ae70f602a · Zeichen 7328–7944 im Abschnitt